Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas

Japanese Journal of Clinical Oncology

Volumn 39, Issue 10, 2009, Pages 625-631

  Liu, Ce ^a   Tian, Gang ^b   Tu, Yanyang ^c   Fu, Jianfang ^d   Lan, Chuan ^b   Wu, Nan ^b  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c 63870 Hospital of the People's Liberation Army   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bone morphogenetic protein 2; Glioma; Prognosis

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BRAIN TISSUE; CANCER GRADING; CANCER SURVIVAL; CANCER TISSUE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHOOL CHILD; TUMOR CELL; BRAIN TUMOR; CANCER STAGING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTION AND FORECASTING;

ADOLESCENT; ADULT; AGED; BONE MORPHOGENETIC PROTEIN 2; BRAIN NEOPLASMS; CHILD; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; YOUNG ADULT;

EID: 70349926138     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp094     Document Type: Article

References (25)

1. Sun B, Chu D, Li W, Chu X, Li Y, Wei D, et al. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol doi:10.1007/s11060-009-9859-7.
2. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000;88:2887.
3. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93-108.
4. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
5. Botchkarev VA, Botchkareva NV, Sharov AA, Funa K, Huber O, Gilchrest BA. Modulation of BMP signaling by noggin is required for induction of the secondary (nontylotrich) hair follicles. J Invest Dermatol 2002;118:3-10.
6. Hsu MY, Rovinsky S, Penmatcha S, Herlyn M, Muirhead D. Bone morphogenetic proteins in melanoma: Angel or devil? Cancer Metastasis Rev 2005;24:251-63.
7. Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 2007;22:1129-47.
8. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22:233-41.
9. Clement JH, Raida M, Sanger J, Bicknell R, Liu J, Naumann A, et al. Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol 2005;27:401-7.
10. Wen XZ, Miyake S, Akiyama Y, Yuasa Y. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 2004;316:100-6.
11. Raida M, Clement JH, Ameri K, Han C, Leek RD, Harris AL. Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int J Oncol 2005;26:1465-70.
12. Langenfeld EM, Bojnowski J, Perone J, Langenfeld J. Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg 2005;80:1028-32.
13. Sugimori K, Matsui K, Motomura H, Tokoro T, Wang J, Higa S, et al. BMP-2 prevents apoptosis of the N1511 chondrocytic cell line through PI3K/ Akt-mediated NF-kappaB activation. J Bone Miner Metab 2005;23:411-9.
14. Le Page C, Puiffe M-L, Meunier L, Zietarska M, de Ladurantaye M, Tonin PN, et al. BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res 2009;2:4.
15. Chen HL, Panchision DM. Concise review: Bone morphogenetic protein pleiotropism in neural stem cells and their derivatives-alternative pathways, convergent signals. Stem Cells 2007;25:63-8.
16. Piccirillo SG, Reynolds BA, Zanetti N. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444:761-5.
17. Lee J, Son MJ, Woolard K. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008;13:69-80.
18. Angley C, Kumar M, Dinsio KJ. Signaling by bone morphogenetic proteins and Smad1 modulates the postnatal differentiation of cerebellar cells. J Neurosci 2003;23:260-8.
19. Peretto P, Dati C, De Marchis S. Expression of the secreted factors noggin and bone morphogenetic proteins in the subependymal layer and olfactory bulb of the adult mouse brain. Neuroscience 2004;128:685-96.
20. Lim DA, Tramontin AD, Trevejo JM. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron 2000;28:713-26.
21. Chattopadhyay N, T-Felt Hansen J, Godbole MM, Brown EM. Transforming growth factor β receptor family ligands inhibit hepatocyte growth factor synthesis and secretion from astrocytoma cells. Mol Brain Res 2004;121:146-50.
22. Bhardwaj G, Murdoch B, Wu D. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2001;2:172-80.
23. Shimogori T, Banuchi V, Strauss JB. Embryonic signaling centers expressing BMP, WNT and FGF proteins interact to pattern the cerebral cortex. Development 2004;131:5639-47.
24. de Jong DS, Steegenga WT, Hendriks JM. Regulation of Notch signaling genes during BMP2-induced differentiation of osteoblast precursor cells. Biochem Biophys Res Commun 2004;320:100-7.
25. Nakayama N, Lee J, Chiu L. Vascular endothelial growth factor synergistically enhances bone morphogenetic protein-4-dependent lymphohematopoietic cell generation from embryonic stem cells in vitro. Blood 2000;95:2275-83.